BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23243218)

  • 21. Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations.
    Chevrier S; Arnould L; Ghiringhelli F; Coudert B; Fumoleau P; Boidot R
    Int J Oncol; 2014 Sep; 45(3):1167-74. PubMed ID: 24990411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients.
    Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
    Cancer Sci; 2006 Jul; 97(7):642-8. PubMed ID: 16827805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity.
    Han HS; Lim SN; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Son SM; Choi SY; Lee HC; Lee OJ
    J Thorac Oncol; 2012 Feb; 7(2):355-64. PubMed ID: 22157369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequently used quantitative polymerase chain reaction-based methods overlook potential clinically relevant genetic alterations in epidermal growth factor receptor compared with next-generation sequencing: a retrospective clinical comparison of 1839 lung adenocarcinomas.
    Tønnesen E; Lade-Keller J; Stougaard M
    Hum Pathol; 2021 Sep; 115():67-75. PubMed ID: 34153308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
    Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
    Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.
    Tsai TH; Wu SG; Chang YL; Wu CT; Tsai MF; Wei PF; Yang CH; Yu CJ; Yang PC; Shih JY
    J Thorac Oncol; 2012 Jun; 7(6):993-1000. PubMed ID: 22525557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens.
    Liu J; Zhao R; Zhang J; Zhang J
    J Cancer Res Clin Oncol; 2015 Feb; 141(2):221-7. PubMed ID: 25156817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accuracy of next-generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma.
    Baum JE; Zhang P; Hoda RS; Geraghty B; Rennert H; Narula N; Fernandes HD
    Cancer Cytopathol; 2017 Jun; 125(6):398-406. PubMed ID: 28272845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
    Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
    Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations.
    Vliegen L; Dooms C; De Kelver W; Verbeken E; Vansteenkiste J; Vandenberghe P
    Diagn Pathol; 2015 May; 10():57. PubMed ID: 26022577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
    Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
    Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.
    Forest F; Stachowicz ML; Casteillo F; Karpathiou G; Gouzy-Grosjean F; Guilaubey C; Cottier M; Beal J; Clemenson A; Péoc'h M
    Exp Mol Pathol; 2017 Dec; 103(3):306-310. PubMed ID: 29175303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical screening assay for EGFR exon 19 mutations using PNA-clamp smart amplification process version 2 in lung adenocarcinoma.
    Araki T; Shimizu K; Nakamura T; Baba M; Kawai Y; Nakamura K; Mitani Y; Obayashi K; Aomori T; Fujita Y; Miyamae Y; Kakegawa S; Kaira K; Lezhava A; Hayashizaki Y; Takeyoshi I; Yamamoto K
    Oncol Rep; 2011 Nov; 26(5):1213-9. PubMed ID: 21769434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Combined test using both cell sediment and supernatant cell-free DNA in pleural effusion shows increased sensitivity in detecting activating EGFR mutation in lung cancer patients.
    Kawahara A; Fukumitsu C; Azuma K; Taira T; Abe H; Takase Y; Murata K; Sadashima E; Hattori S; Naito Y; Akiba J
    Cytopathology; 2018 Apr; 29(2):150-155. PubMed ID: 29363841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm.
    De Luca C; Rappa AG; Gragnano G; Malapelle U; Troncone G; Barberis M
    J Clin Pathol; 2018 Aug; 71(8):745-750. PubMed ID: 29798838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Epidermal Growth Factor Receptor Gene Mutations Identified Using Pleural Effusion and Primary Tumor Tissue Samples in Non-Small Cell Lung Cancer.
    Liu N; Sun RZ; Du J; Dong QZ; Fan CF; Li QC; Wang EH; Liu Y
    Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):e44-e51. PubMed ID: 28800007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman.
    Bonanno L; Calabrese F; Nardo G; Calistri D; Tebaldi M; Tedaldi G; Polo V; Vuljan S; Favaretto A; Conte P; Amadori A; Rea F; Indraccolo S
    Lung Cancer; 2016 Jun; 96():52-5. PubMed ID: 27133750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different next-generation sequencing pipelines based detection of tumor DNA in cerebrospinal fluid of lung adenocarcinoma cancer patients with leptomeningeal metastases.
    Ge M; Zhan Q; Zhang Z; Ji X; Zhou X; Huang R; Liang X
    BMC Cancer; 2019 Feb; 19(1):143. PubMed ID: 30755180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of BRAF
    Pierry C; Caumont C; Blanchard E; Brochet C; Dournes G; Gros A; Bandres T; Verdon S; Marty M; Bégueret H; Merlio JP
    Virchows Arch; 2018 Feb; 472(2):247-258. PubMed ID: 28711990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Evaluation of Consistency in detection of epidermal growth factor receptor gene T790M mutation in plasma and tumor specimens of patients with lung adenocarcinoma].
    Du J; Wang Z; Yang L; Di J; Zhang JG; Wang TY; Liu DG
    Zhonghua Zhong Liu Za Zhi; 2018 Jan; 40(1):35-39. PubMed ID: 29365415
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.